There is a single Institutional Review Board (IRB) that approves protocols for both institutions. After the University of Iowa’s IRB has approved the protocols the Research and Development Committee of the ICVAHCS meets to provide their approval for the study. Patient Recruitment: The UIHC and ICVAHCS draw from a large catchment area that will ensure the enrollment of sufficient numbers of men into the protocol. We will use recruitment methods similar to the methods used to obtain subjects for our Phase I clinical trial. That includes contacting patients that are being or have been treated in the Departments of Urology, Internal Medicine, and Radiation Oncology at the UIHC and ICVAHCS and letters written to urologists, oncologists, and medical oncologists in Iowa and the neighboring states of Wisconsin, Illinois, Missouri, Nebraska, Minnesota, and South Dakota. Drs.